Complete Filing Data
Telomir Pharmaceuticals, Inc. reported Stockholders Equity of $5.91 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Telomir Pharmaceuticals, Inc. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Net Income Loss | -$10.4M | -$16.5M | -$13.1M | -$854.1K |
| Research And Development Expense | $2.4M | $2.2M | $1.6M | $833.2K |
| Operating Expenses | $10.5M | $12.2M | $3.9M | $854.1K |
| General And Administrative Expense | $8.1M | $9.6M | $600.2K | $20.9K |
| Interest Expense Nonoperating | $4.3M | $1.6M | ||
| Nonoperating Income Expense | ||||
| Interest Income Expense Nonoperating Net | ||||
| Interest Expense | $1.6M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income Loss | -$1.1M | -$5.1M | -$2.2M | -$6.0M | -$1.4M | -$6.3M | -$9.3M | -$1.7M | -$1.6M | -$482.9K |
| Research And Development Expense | $759.5K | $42.8K | $337.0K | $627.4K | $594.8K | $804.0K | $262.6K | $667.6K | $440.3K | |
| Operating Expenses | $1.1M | $5.1M | $2.2M | $6.0M | $1.5M | $1.9M | $954.2K | $1.4M | $482.9K | |
| General And Administrative Expense | $387.0K | $5.0M | $1.9M | $5.4M | $879.7K | $741.5K | $102.2K | $60.1K | $42.6K | |
| Interest Expense Nonoperating | $1.3K | $757.2K | $124.1K | |||||||
| Nonoperating Income Expense | $15.4K | -$757.2K | ||||||||
| Interest Income Expense Nonoperating Net | $8.0K | -$4.3M | ||||||||
| Interest Expense | $4.3M |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Stockholders Equity | $5.9M | $643.0K | $3.4M | -$937.3K | -$138.1K |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | $7.3M | $1.3M | $1.2K | $1.4K | |
| Retained Earnings Accumulated Deficit | -$41.0M | -$30.6M | -$14.1M | -$992.3K | |
| Liabilities Current | $1.4M | $681.0K | $1.3M | $986.0K | |
| Liabilities And Stockholders Equity | $7.3M | $1.3M | $4.8M | $48.7K | |
| Liabilities | $1.4M | $681.0K | $1.3M | $986.0K | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | $6.0M | $1.3M | -$188.00 | $1.4K | |
| Assets Current | $7.3M | $1.3M | $435.2K | $48.7K | |
| Assets | $7.3M | $1.3M | $4.8M | $48.7K | |
| Accounts Payable And Accrued Liabilities Current | $536.8K | $587.5K | $707.2K | $404.2K | |
| Cash | |||||
| Other Liabilities Current | $318.2K | $93.4K | $527.4K | ||
| Other Liabilities | $581.8K | ||||
| Repayments Of Related Party Debt | |||||
| Other Receivables | |||||
| Deferred Offering Costs | $303.3K | $47.3K | |||
| Deferred Costs | $4.3M | ||||
| Accrued Offering Expense | $90.0K | ||||
| Cash And Cash Equivalents At Carrying Value | |||||
| Gains Losses On Extinguishment Of Debt | -$7.5M | ||||
| Deferred Offering Costs Charged To Additional Paidin Capital | $303.3K | ||||
| Deferred Finance Costs | $6.0M | ||||
| Debt Conversion To Common Stock | $3.1M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | $7.0M | $481.2K | -$161.1K | $442.1K | $1.6M | $3.0M | $2.2M | $3.9M | -$510.2K | ||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | $7.3M | $754.3K | $403.0K | $834.6K | $1.9M | $3.3M | $2.5K | $14.6K | $1.8K | ||
| Retained Earnings Accumulated Deficit | -$38.9M | -$37.8M | -$32.8M | -$27.7M | -$21.8M | -$20.3M | |||||
| Liabilities Current | $422.8K | $348.4K | $652.3K | $599.9K | $534.2K | $486.6K | |||||
| Liabilities And Stockholders Equity | $7.4M | $829.6K | $491.2K | $1.0M | $2.1M | $3.5M | |||||
| Liabilities | $422.8K | $348.4K | $652.3K | $599.9K | $534.2K | $486.6K | |||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -$863.1K | $3.3M | $388.00 | ||||||||
| Assets Current | $7.4M | $829.6K | $491.2K | $1.0M | $2.1M | $3.5M | |||||
| Assets | $7.4M | $829.6K | $491.2K | $1.0M | $2.1M | $3.5M | |||||
| Accounts Payable And Accrued Liabilities Current | $329.4K | $255.0K | $558.9K | $506.5K | $393.8K | $478.7K | |||||
| Cash | $754.3K | $403.0K | $1.3M | ||||||||
| Other Liabilities Current | $93.4K | $93.4K | $93.4K | ||||||||
| Other Liabilities | $93.4K | $140.3K | $7.9K | $527.4K | |||||||
| Repayments Of Related Party Debt | $519.5K | $263.9K | |||||||||
| Other Receivables | $130.0K | $130.0K | $130.0K | $130.0K | |||||||
| Deferred Offering Costs | |||||||||||
| Deferred Costs | |||||||||||
| Accrued Offering Expense | $118.9K | ||||||||||
| Cash And Cash Equivalents At Carrying Value | $754.3K | $403.0K | $1.3M | ||||||||
| Gains Losses On Extinguishment Of Debt | |||||||||||
| Deferred Offering Costs Charged To Additional Paidin Capital | |||||||||||
| Deferred Finance Costs | |||||||||||
| Debt Conversion To Common Stock |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Net Cash Provided By Used In Operating Activities | -$3.7M | -$5.1M | -$3.9M | -$468.7K |
| Increase Decrease In Accounts Payable And Accrued Liabilities | -$50.8K | $183.6K | $114.6K | $385.5K |
| Net Cash Provided By Used In Financing Activities | $9.7M | $6.3M | $3.9M | $470.1K |
| Increase Decrease In Prepaid Expense | -$3.2K | $57.2K | $713.00 | |
| Proceeds From Issuance Of Common Stock | $6.8M | $1.0M | ||
| Proceeds From Repayments Of Related Party Debt | -$433.9K | $1.7M | $462.4K | |
| Share Based Compensation | $5.3M | $6.9M | ||
| Proceeds From Related Party Debt | $1.7M | |||
| Proceeds From Lines Of Credit | $1.5M | |||
| Payments For Fees | $90.0K | |||
| Payments Of Debt Issuance Costs | $256.0K | |||
| Stock Issued During Period Value Share Based Compensation | ||||
| Proceeds From Warrant Exercises | $37.3K | |||
| Proceeds From Sale Of Common Stock | $6.6M | $6.8M | ||
| Payments Of Financing Costs | $256.0K | $47.3K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q2 2025 | Q1 2025 | Q1 2024 | Q1 2023 |
|---|---|---|---|---|
| Net Cash Provided By Used In Operating Activities | -$863.1K | -$1.9M | -$735.7K | |
| Increase Decrease In Accounts Payable And Accrued Liabilities | -$28.7K | $74.7K | -$252.8K | |
| Net Cash Provided By Used In Financing Activities | $5.2M | $736.1K | ||
| Increase Decrease In Prepaid Expense | $30.3K | $98.1K | ||
| Proceeds From Issuance Of Common Stock | $5.8M | $1.0M | ||
| Proceeds From Repayments Of Related Party Debt | ||||
| Share Based Compensation | $1.4M | |||
| Proceeds From Related Party Debt | ||||
| Proceeds From Lines Of Credit | ||||
| Payments For Fees | $100.0K | |||
| Payments Of Debt Issuance Costs | ||||
| Stock Issued During Period Value Share Based Compensation | $3.8M | $1.4M | ||
| Proceeds From Warrant Exercises | ||||
| Proceeds From Sale Of Common Stock | ||||
| Payments Of Financing Costs |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 31.7M | 29.5M | 27.3M | 26.8M |
| Weighted Average Number Of Diluted Shares Outstanding | 31.7M | 29.5M | 27.3M | 26.8M |
| Earnings Per Share Diluted | $-0.33 | $-0.56 | $0.48 | $-0.03 |
| Earnings Per Share Basic | $-0.33 | $-0.56 | $0.48 | $-0.03 |
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 |
| Preferred Stock Shares Outstanding | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock Shares Issued | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock Shares Authorized | 100.0M | 100.0M | 100.0M | 100.0M |
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 |
| Common Stock Shares Outstanding | 34.4M | 29.8M | 28.6M | 26.8M |
| Common Stock Shares Issued | 34.4M | 29.8M | 28.6M | 26.8M |
| Common Stock Shares Authorized | 300.0M | 300.0M | 300.0M | 300.0M |
| Stock Issued During Period Shares Issued For Services | 400.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 32.4M | 30.0M | 29.8M | 29.6M | 29.6M | 29.3M | 27.1M | 27.1M | 26.9M |
| Weighted Average Number Of Diluted Shares Outstanding | 32.4M | 30.0M | 29.8M | 29.6M | 29.6M | 29.3M | 27.1M | 27.1M | 26.9M |
| Earnings Per Share Diluted | $-0.03 | $0.17 | $-0.07 | $-0.20 | $0.05 | $-0.23 | $-0.06 | $-0.06 | $-0.02 |
| Earnings Per Share Basic | $-0.03 | $0.17 | $-0.07 | $-0.20 | $0.05 | $-0.23 | $-0.06 | $-0.06 | $-0.02 |
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |||
| Preferred Stock Shares Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Preferred Stock Shares Issued | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Preferred Stock Shares Authorized | 100.0M | 100.0M | 100.0M | 100.0M | 100.0M | 100.0M | |||
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |||
| Common Stock Shares Outstanding | 33.8M | 30.5M | 29.8M | 29.6M | 29.6M | 29.6M | |||
| Common Stock Shares Issued | 33.8M | 30.5M | 29.8M | 29.6M | 29.6M | 29.6M | |||
| Common Stock Shares Authorized | 300.0M | 300.0M | 300.0M | 300.0M | 300.0M | 300.0M | |||
| Stock Issued During Period Shares Issued For Services |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Additional Paid In Capital | $46.9M | $31.2M | $17.5M | $55.0K |
| Prepaid Expense Current | $54.7K | $57.9K | $713.00 | |
| Stock Issued During Period Value New Issues | $6.6M | $6.8M | $910.0K | |
| Travel And Entertainment Expense | $370.5K | $1.8M | ||
| Amortization Of Financing Costs | $4.3M | $1.6M | ||
| Investment Income Interest | $125.6K | $48.0K | ||
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $5.3M | $6.9M | ||
| Repayments Of Lines Of Credit | $101.0K | |||
| Stock Issued During Period Value Issued For Services | $840.0K | |||
| Adjustments To Additional Paid In Capital Warrant Issued | $6.0M | |||
| Stock Issued During Period Value Other | $3.0M | $55.0K | ||
| Lines Of Credit Current | $101.0K | |||
| Interest Income Other | $48.0K | |||
| Issuance Of Warrants On Related Party Line Of Credit | $6.0M | |||
| Stock Issued During Period Value Conversion Of Convertible Securities | $10.6M | |||
| Stock Issued During Period Value Warrants Exercised | $37.3K | |||
| Stock Issued During Period Shares New Issues | 666.7K | |||
| Provision For Other Credit Losses | $130.0K | |||
| Issuance Of Stock And Warrants For Services Or Claims | $840.0K | |||
| Advances To Affiliates | $130.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| Additional Paid In Capital | $45.9M | $38.3M | $32.6M | $28.1M | $23.3M | $23.3M | ||||
| Prepaid Expense Current | $72.8K | $75.3K | $88.2K | $77.3K | $87.8K | $98.8K | ||||
| Stock Issued During Period Value New Issues | $5.5M | $47.8K | $5.8M | |||||||
| Travel And Entertainment Expense | $370.5K | $589.4K | $698.6K | |||||||
| Amortization Of Financing Costs | $4.3M | |||||||||
| Investment Income Interest | $44.2K | $1.4K | $15.4K | $25.5K | ||||||
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $98.1K | $3.8M | $1.4M | $4.8M | ||||||
| Repayments Of Lines Of Credit | $101.0K | |||||||||
| Stock Issued During Period Value Issued For Services | $840.0K | |||||||||
| Adjustments To Additional Paid In Capital Warrant Issued | $6.0M | |||||||||
| Stock Issued During Period Value Other | $2.0M | $1.0M | $910.0K | |||||||
| Lines Of Credit Current | ||||||||||
| Interest Income Other | $15.4K | $25.5K | ||||||||
| Issuance Of Warrants On Related Party Line Of Credit | ||||||||||
| Stock Issued During Period Value Conversion Of Convertible Securities | $10.6M | |||||||||
| Stock Issued During Period Value Warrants Exercised | ||||||||||
| Stock Issued During Period Shares New Issues | ||||||||||
| Provision For Other Credit Losses | ||||||||||
| Issuance Of Stock And Warrants For Services Or Claims | ||||||||||
| Advances To Affiliates |
Most recent annual filing with the SEC: March 17, 2026
Data sourced from SEC EDGAR public filings as of August 6, 2026.